Novavax (NVAX) Non-Current Deferred Tax Liability (2018 - 2019)

Novavax (NVAX) recorded quarterly Non-Current Deferred Tax Liability of $2.5 million in Q4 2019, down 20.96% quarter-over-quarter from $3.2 million in Q4 2018, and down 20.96% on a YoY basis from $3.2 million in Q4 2018.

Novavax (NVAX) Non-Current Deferred Tax Liability (2018 - 2019) Analysis & Trends

Novavax's Non-Current Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $2.5 million for Q4 2019.

  • In Q4 2019, Non-Current Deferred Tax Liability fell 20.96% year-over-year to $2.5 million; the TTM figure through Dec 2019 stood at $2.5 million (down 20.96% YoY), while the FY2019 annual figure was $2.5 million, down 20.96% from the prior year.
  • Non-Current Deferred Tax Liability was $2.5 million for Q4 2019 at Novavax, down from $3.2 million in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $3.2 million in Q4 2018 to a low of $2.5 million in Q4 2019.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Novavax 1.49 Bn 931.98 Mn 108.82 Mn

Historic Data

Download Data
DateValue
Dec 31, 2019 2.51 Mn
Dec 31, 2019 2.51 Mn
Dec 31, 2018 3.18 Mn
Dec 31, 2018 3.18 Mn